Web Exclusives

Web Exclusives | December 22, 2021
Recently released results using liquid biopsy shows KRAS G12C mutation in patients with NSCLC can be lost or acquired at progressive disease.
Web Exclusives | December 22, 2021
Social listening can offer investigators valuable information about unmet patient needs and concerns regarding their cancer treatment and to direct future research.
Web Exclusives | December 22, 2021
Researchers found a large underrepresentation gap among minority populations across major cancer types in clinical trials.
Web Exclusives | December 22, 2021
Improved understanding of self-care behaviors in patients with cancer who take oral anticancer medications can help healthcare professionals support patient medication adherence.
Web Exclusives | December 20, 2021
Providing quality care requires understanding the disease factors, clinical presentation, and management strategies for immunotherapy-induced cytokine release syndrome with acute lymphoblastic leukemia treatment.
Web Exclusives | December 20, 2021
An overview of the clinical presentation, management approaches, and clinical practice guidelines for immunotherapy-related neurotoxicity in acute lymphoblastic leukemia treatment is presented.
Web Exclusives | December 20, 2021
Clinicians should recognize the prognostic importance of minimal residual disease testing and its implications for treatment pathways in acute lymphoblastic leukemia.
Web Exclusives | December 20, 2021
Navigating the complexities of acute lymphoblastic leukemia treatment requires a multidisciplinary team approach to the management of multiple care needs in inpatient and outpatient settings.
Web Exclusives | December 20, 2021
Successful transitions of care from the hospital to the home setting for patients with acute lymphoblastic leukemia requires a team of hospital and outpatient clinicians to provide coordinated care and support.
Web Exclusives | December 14, 2021
In a follow-up analysis, second-line nivolumab in advanced/recurrent esophageal squamous-cell carcinoma showed significant median overall survival benefit compared with chemotherapy.
Web Exclusives | December 14, 2021
Promising antitumor activity and a tolerable safety profile were found in patients with previously treated gastric or gastroesophageal cancer treated with trifluridine/tipiracil combined with ramucirumab.
Web Exclusives | December 14, 2021
Insertion-deletion rate and high tumor mutation burden in advanced gastric cancer was found to be associated with favorable progression-free survival and overall survival in patients treated with nivolumab.
Web Exclusives | December 14, 2021
Treatment with surufatinib in combination with toripalimab is associated with promising responses and manageable adverse events in previously treated gastric or gastroesophageal junction adenocarcinoma.
Web Exclusives | December 14, 2021
Post-hoc analysis of the CheckMate-032 study found PD-L1 expression by combined positive score was more closely associated with nivolumab and ipilimumab therapy efficacy compared with percentage of positive tumor cells PD-L1 expression in advanced gastric/gastroesophageal junction cancer.
Web Exclusives | December 14, 2021
Progression-free survival and overall survival improved more after treatment with ramucirumab plus paclitaxel compared with placebo plus paclitaxel in Asian patients with advanced gastric and gastroesophageal junction cancer who were previously treated with chemotherapy.
Web Exclusives | December 14, 2021
Progression-free survival and overall survival improved more after treatment with ramucirumab plus paclitaxel compared with placebo plus paclitaxel in Asian patients with advanced gastric and gastroesophageal junction cancer who were previously treated with chemotherapy.
Web Exclusives | December 14, 2021
Nivolumab with paclitaxel plus ramucirumab as second-line therapy in patients with advanced gastric cancer demonstrated promising responses with manageable treatment-related adverse events.
Web Exclusives | December 10, 2021
Dr Steven Rowe expands on the sensitivity and specificity of PYLARIFY® (piflufolastat F 18) imaging in high-risk prostate cancer.
Web Exclusives | December 2, 2021
Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer.
Web Exclusives | November 23, 2021
Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent.
Web Exclusives | November 19, 2021
A recently released MYLUNG study found that most patients with untreated metastatic NSCLC tested for ≥1 biomarkers, but <50% of patients had ≥5 biomarker tests.
Web Exclusives | November 19, 2021
Recently released clinical trial results evaluating the effect of early integration of interdisciplinary supportive care found improvement in quality of life, mood, and nutritional status in patients with NSCLC.
Web Exclusives | November 19, 2021
Caregivers and patients report better understanding of precision medicine and reduced patient anxiety with implementation of a therapeutic patient education program.
Web Exclusives | November 19, 2021
Study results reveal that KRAS G12C mutations vary according to sex and ethnicity in patients with cancer.
Web Exclusives | November 16, 2021
Nivolumab plus chemotherapy in patients with advanced gastric cancer, esophageal adenocarcinoma, or gastroesophageal junction cancer led to significantly higher health-related quality-of-life scores than in patients receiving chemotherapy alone.
Web Exclusives | November 16, 2021
KEYNOTE-590 study results demonstrate improved overall survival and progression-free survival across subgroups for treatment-naïve patients with advanced esophageal cancer receiving pembrolizumab combined with chemotherapy.
Web Exclusives | November 16, 2021
Patients with previously treated advanced or metastatic gastric cancer receiving sintilimab showed a modest response rate and an acceptable safety profile.
Web Exclusives | November 16, 2021
Recently released clinical trial results show that bavituximab in combination with pembrolizumab had promising antitumor activity and was well-tolerated in patients with advanced gastric or gastroesophageal cancer.
Web Exclusives | November 16, 2021
Patients with treatment-naïve advanced or metastatic esophageal squamous-cell carcinoma receiving combination toripalimab and chemotherapy saw significant progression-free survival and overall survival improvement.
Web Exclusives | November 16, 2021
Clinical trial results demonstrate nivolumab combined with chemotherapy conveys improvement in overall response rate and progression-free survival in patients with recurrent or advanced gastric cancer.
Page 1 of 7
Results 1 - 30 of 182

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code